RxDoctor Payments Data

Tracey Lindeman, MD

Internal Medicine · Webster, TXNPI 1154765865

Payments from drug & device makers

$2,025in general payments, 2019–2025

Across 104 payments — averaging $19.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$394
  • Lilly USA, LLC$329
  • AstraZeneca$285
  • Novo Nordisk$249
  • Amgen$230
  • Smith+Nephew$135
  • plus $403 from 10 others

What the payments were for

  • Food & beverage$2,025100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,025 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$112,455
Medicare patients
391
Services billed
1,035

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide72$116,570
JardianceEmpagliflozin68$89,529
EliquisApixaban44$62,763
FarxigaDapagliflozin Propanediol23$25,472
XareltoRivaroxaban14$22,505
TrulicityDulaglutide19$20,627
JanuviaSitagliptin Phosphate21$16,721
SynthroidLevothyroxine Sodium130$6,506
Levothyroxine Sodium435$5,428
Losartan Potassium385$4,897
Atorvastatin Calcium443$3,805
Rosuvastatin Calcium276$3,733
Bupropion XlBupropion Hcl65$3,214
Potassium Chloride74$2,254
Pravastatin Sodium134$2,213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$249$116,57072 claims
PfizerEliquis$394$62,76344 claims
AstraZenecaFarxiga$285$25,47223 claims
Johnson & JohnsonXarelto$41$22,50514 claims
Lilly USA, LLCTrulicity$329$20,62719 claims
MerckJanuvia$22$16,72121 claims
AbbVieSynthroid$40$6,506130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Webster

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →